Atossa Therapeutics, Inc.
Atossa Therapeutics, Inc. (ATOS) Stock Competitors & Peer Comparison
See (ATOS) competitors and their performances in Stock Market.
Peer Comparison Table: Biotechnology Industry
Detailed financial metrics including price, market cap, P/E ratio, and more.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| ATOS | $4.53 | -3.21% | 39.1M | -1.31 | -$3.45 | N/A |
| VRTX | $456.69 | -0.90% | 116B | 30.88 | $14.79 | N/A |
| REGN | $759.86 | -0.66% | 79B | 18.33 | $41.46 | +0.47% |
| VRNA | $106.91 | +0.11% | 72.7B | -102.80 | -$1.04 | N/A |
| ARGX | $717.80 | -1.42% | 44.4B | 30.69 | $23.39 | N/A |
| SGEN | $228.74 | -0.07% | 43.2B | -57.19 | -$4.00 | N/A |
| ALNY | $320.66 | +0.05% | 42.5B | 140.64 | $2.28 | N/A |
| INSM | $140.13 | -2.40% | 30.2B | -21.83 | -$6.42 | N/A |
| BNTX | $101.50 | -0.44% | 24.4B | -36.12 | -$2.81 | N/A |
| UTHR | $478.16 | -1.42% | 21B | 17.18 | $27.84 | N/A |
Stock Comparison
ATOS vs VRTX Comparison March 2026
ATOS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ATOS stands at 39.1M. In comparison, VRTX has a market cap of 116B. Regarding current trading prices, ATOS is priced at $4.53, while VRTX trades at $456.69.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ATOS currently has a P/E ratio of -1.31, whereas VRTX's P/E ratio is 30.88. In terms of profitability, ATOS's ROE is -0.49%, compared to VRTX's ROE of +0.23%. Regarding short-term risk, ATOS is more volatile compared to VRTX. This indicates potentially higher risk in terms of short-term price fluctuations for ATOS.Check VRTX's competition here
ATOS vs REGN Comparison March 2026
ATOS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ATOS stands at 39.1M. In comparison, REGN has a market cap of 79B. Regarding current trading prices, ATOS is priced at $4.53, while REGN trades at $759.86.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ATOS currently has a P/E ratio of -1.31, whereas REGN's P/E ratio is 18.33. In terms of profitability, ATOS's ROE is -0.49%, compared to REGN's ROE of +0.15%. Regarding short-term risk, ATOS is more volatile compared to REGN. This indicates potentially higher risk in terms of short-term price fluctuations for ATOS.Check REGN's competition here
ATOS vs VRNA Comparison March 2026
ATOS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ATOS stands at 39.1M. In comparison, VRNA has a market cap of 72.7B. Regarding current trading prices, ATOS is priced at $4.53, while VRNA trades at $106.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ATOS currently has a P/E ratio of -1.31, whereas VRNA's P/E ratio is -102.80. In terms of profitability, ATOS's ROE is -0.49%, compared to VRNA's ROE of -0.30%. Regarding short-term risk, ATOS is more volatile compared to VRNA. This indicates potentially higher risk in terms of short-term price fluctuations for ATOS.Check VRNA's competition here
ATOS vs ARGX Comparison March 2026
ATOS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ATOS stands at 39.1M. In comparison, ARGX has a market cap of 44.4B. Regarding current trading prices, ATOS is priced at $4.53, while ARGX trades at $717.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ATOS currently has a P/E ratio of -1.31, whereas ARGX's P/E ratio is 30.69. In terms of profitability, ATOS's ROE is -0.49%, compared to ARGX's ROE of +0.34%. Regarding short-term risk, ATOS is more volatile compared to ARGX. This indicates potentially higher risk in terms of short-term price fluctuations for ATOS.Check ARGX's competition here
ATOS vs SGEN Comparison March 2026
ATOS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ATOS stands at 39.1M. In comparison, SGEN has a market cap of 43.2B. Regarding current trading prices, ATOS is priced at $4.53, while SGEN trades at $228.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ATOS currently has a P/E ratio of -1.31, whereas SGEN's P/E ratio is -57.19. In terms of profitability, ATOS's ROE is -0.49%, compared to SGEN's ROE of -0.21%. Regarding short-term risk, ATOS is more volatile compared to SGEN. This indicates potentially higher risk in terms of short-term price fluctuations for ATOS.Check SGEN's competition here
ATOS vs ALNY Comparison March 2026
ATOS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ATOS stands at 39.1M. In comparison, ALNY has a market cap of 42.5B. Regarding current trading prices, ATOS is priced at $4.53, while ALNY trades at $320.66.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ATOS currently has a P/E ratio of -1.31, whereas ALNY's P/E ratio is 140.64. In terms of profitability, ATOS's ROE is -0.49%, compared to ALNY's ROE of +0.90%. Regarding short-term risk, ATOS is more volatile compared to ALNY. This indicates potentially higher risk in terms of short-term price fluctuations for ATOS.Check ALNY's competition here
ATOS vs INSM Comparison March 2026
ATOS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ATOS stands at 39.1M. In comparison, INSM has a market cap of 30.2B. Regarding current trading prices, ATOS is priced at $4.53, while INSM trades at $140.13.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ATOS currently has a P/E ratio of -1.31, whereas INSM's P/E ratio is -21.83. In terms of profitability, ATOS's ROE is -0.49%, compared to INSM's ROE of -1.68%. Regarding short-term risk, ATOS is more volatile compared to INSM. This indicates potentially higher risk in terms of short-term price fluctuations for ATOS.Check INSM's competition here
ATOS vs BNTX Comparison March 2026
ATOS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ATOS stands at 39.1M. In comparison, BNTX has a market cap of 24.4B. Regarding current trading prices, ATOS is priced at $4.53, while BNTX trades at $101.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ATOS currently has a P/E ratio of -1.31, whereas BNTX's P/E ratio is -36.12. In terms of profitability, ATOS's ROE is -0.49%, compared to BNTX's ROE of -0.03%. Regarding short-term risk, ATOS is more volatile compared to BNTX. This indicates potentially higher risk in terms of short-term price fluctuations for ATOS.Check BNTX's competition here
ATOS vs UTHR Comparison March 2026
ATOS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ATOS stands at 39.1M. In comparison, UTHR has a market cap of 21B. Regarding current trading prices, ATOS is priced at $4.53, while UTHR trades at $478.16.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ATOS currently has a P/E ratio of -1.31, whereas UTHR's P/E ratio is 17.18. In terms of profitability, ATOS's ROE is -0.49%, compared to UTHR's ROE of +0.19%. Regarding short-term risk, ATOS is more volatile compared to UTHR. This indicates potentially higher risk in terms of short-term price fluctuations for ATOS.Check UTHR's competition here
ATOS vs MRNA Comparison March 2026
ATOS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ATOS stands at 39.1M. In comparison, MRNA has a market cap of 20.7B. Regarding current trading prices, ATOS is priced at $4.53, while MRNA trades at $52.52.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ATOS currently has a P/E ratio of -1.31, whereas MRNA's P/E ratio is -7.23. In terms of profitability, ATOS's ROE is -0.49%, compared to MRNA's ROE of -0.30%. Regarding short-term risk, ATOS is less volatile compared to MRNA. This indicates potentially lower risk in terms of short-term price fluctuations for ATOS.Check MRNA's competition here
ATOS vs ROIV Comparison March 2026
ATOS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ATOS stands at 39.1M. In comparison, ROIV has a market cap of 20.6B. Regarding current trading prices, ATOS is priced at $4.53, while ROIV trades at $28.78.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ATOS currently has a P/E ratio of -1.31, whereas ROIV's P/E ratio is -24.60. In terms of profitability, ATOS's ROE is -0.49%, compared to ROIV's ROE of -0.18%. Regarding short-term risk, ATOS is more volatile compared to ROIV. This indicates potentially higher risk in terms of short-term price fluctuations for ATOS.Check ROIV's competition here
ATOS vs BGNE Comparison March 2026
ATOS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ATOS stands at 39.1M. In comparison, BGNE has a market cap of 20.2B. Regarding current trading prices, ATOS is priced at $4.53, while BGNE trades at $184.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ATOS currently has a P/E ratio of -1.31, whereas BGNE's P/E ratio is -22.55. In terms of profitability, ATOS's ROE is -0.49%, compared to BGNE's ROE of +0.07%. Regarding short-term risk, ATOS is more volatile compared to BGNE. This indicates potentially higher risk in terms of short-term price fluctuations for ATOS.Check BGNE's competition here
ATOS vs RVMD Comparison March 2026
ATOS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ATOS stands at 39.1M. In comparison, RVMD has a market cap of 19.5B. Regarding current trading prices, ATOS is priced at $4.53, while RVMD trades at $98.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ATOS currently has a P/E ratio of -1.31, whereas RVMD's P/E ratio is -18.95. In terms of profitability, ATOS's ROE is -0.49%, compared to RVMD's ROE of -0.63%. Regarding short-term risk, ATOS is more volatile compared to RVMD. This indicates potentially higher risk in terms of short-term price fluctuations for ATOS.Check RVMD's competition here
ATOS vs RPRX Comparison March 2026
ATOS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ATOS stands at 39.1M. In comparison, RPRX has a market cap of 19.5B. Regarding current trading prices, ATOS is priced at $4.53, while RPRX trades at $45.41.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ATOS currently has a P/E ratio of -1.31, whereas RPRX's P/E ratio is 25.51. In terms of profitability, ATOS's ROE is -0.49%, compared to RPRX's ROE of +0.12%. Regarding short-term risk, ATOS is more volatile compared to RPRX. This indicates potentially higher risk in terms of short-term price fluctuations for ATOS.Check RPRX's competition here
ATOS vs INCY Comparison March 2026
ATOS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ATOS stands at 39.1M. In comparison, INCY has a market cap of 19.1B. Regarding current trading prices, ATOS is priced at $4.53, while INCY trades at $95.94.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ATOS currently has a P/E ratio of -1.31, whereas INCY's P/E ratio is 15.25. In terms of profitability, ATOS's ROE is -0.49%, compared to INCY's ROE of +0.29%. Regarding short-term risk, ATOS is more volatile compared to INCY. This indicates potentially higher risk in terms of short-term price fluctuations for ATOS.Check INCY's competition here
ATOS vs DNA-WT Comparison March 2026
ATOS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ATOS stands at 39.1M. In comparison, DNA-WT has a market cap of 18.7B. Regarding current trading prices, ATOS is priced at $4.53, while DNA-WT trades at $0.27.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ATOS currently has a P/E ratio of -1.31, whereas DNA-WT's P/E ratio is N/A. In terms of profitability, ATOS's ROE is -0.49%, compared to DNA-WT's ROE of -0.54%. Regarding short-term risk, ATOS is less volatile compared to DNA-WT. This indicates potentially lower risk in terms of short-term price fluctuations for ATOS.Check DNA-WT's competition here
ATOS vs GMAB Comparison March 2026
ATOS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ATOS stands at 39.1M. In comparison, GMAB has a market cap of 16.7B. Regarding current trading prices, ATOS is priced at $4.53, while GMAB trades at $27.06.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ATOS currently has a P/E ratio of -1.31, whereas GMAB's P/E ratio is 17.57. In terms of profitability, ATOS's ROE is -0.49%, compared to GMAB's ROE of +0.11%. Regarding short-term risk, ATOS is more volatile compared to GMAB. This indicates potentially higher risk in terms of short-term price fluctuations for ATOS.Check GMAB's competition here
ATOS vs ASND Comparison March 2026
ATOS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ATOS stands at 39.1M. In comparison, ASND has a market cap of 14.8B. Regarding current trading prices, ATOS is priced at $4.53, while ASND trades at $240.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ATOS currently has a P/E ratio of -1.31, whereas ASND's P/E ratio is -55.07. In terms of profitability, ATOS's ROE is -0.49%, compared to ASND's ROE of +1.28%. Regarding short-term risk, ATOS is more volatile compared to ASND. This indicates potentially higher risk in terms of short-term price fluctuations for ATOS.Check ASND's competition here
ATOS vs BBIO Comparison March 2026
ATOS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ATOS stands at 39.1M. In comparison, BBIO has a market cap of 12.7B. Regarding current trading prices, ATOS is priced at $4.53, while BBIO trades at $65.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ATOS currently has a P/E ratio of -1.31, whereas BBIO's P/E ratio is -17.29. In terms of profitability, ATOS's ROE is -0.49%, compared to BBIO's ROE of +0.39%. Regarding short-term risk, ATOS is more volatile compared to BBIO. This indicates potentially higher risk in terms of short-term price fluctuations for ATOS.Check BBIO's competition here
ATOS vs KRTX Comparison March 2026
ATOS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ATOS stands at 39.1M. In comparison, KRTX has a market cap of 12.6B. Regarding current trading prices, ATOS is priced at $4.53, while KRTX trades at $329.83.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ATOS currently has a P/E ratio of -1.31, whereas KRTX's P/E ratio is -28.09. In terms of profitability, ATOS's ROE is -0.49%, compared to KRTX's ROE of -0.36%. Regarding short-term risk, ATOS is more volatile compared to KRTX. This indicates potentially higher risk in terms of short-term price fluctuations for ATOS.Check KRTX's competition here
ATOS vs IONS Comparison March 2026
ATOS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ATOS stands at 39.1M. In comparison, IONS has a market cap of 12.2B. Regarding current trading prices, ATOS is priced at $4.53, while IONS trades at $74.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ATOS currently has a P/E ratio of -1.31, whereas IONS's P/E ratio is -31.11. In terms of profitability, ATOS's ROE is -0.49%, compared to IONS's ROE of -0.69%. Regarding short-term risk, ATOS is more volatile compared to IONS. This indicates potentially higher risk in terms of short-term price fluctuations for ATOS.Check IONS's competition here
ATOS vs BMRN Comparison March 2026
ATOS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ATOS stands at 39.1M. In comparison, BMRN has a market cap of 11.8B. Regarding current trading prices, ATOS is priced at $4.53, while BMRN trades at $61.12.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ATOS currently has a P/E ratio of -1.31, whereas BMRN's P/E ratio is 33.96. In terms of profitability, ATOS's ROE is -0.49%, compared to BMRN's ROE of +0.06%. Regarding short-term risk, ATOS is more volatile compared to BMRN. This indicates potentially higher risk in terms of short-term price fluctuations for ATOS.Check BMRN's competition here
ATOS vs SMMT Comparison March 2026
ATOS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ATOS stands at 39.1M. In comparison, SMMT has a market cap of 11.2B. Regarding current trading prices, ATOS is priced at $4.53, while SMMT trades at $15.11.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ATOS currently has a P/E ratio of -1.31, whereas SMMT's P/E ratio is -10.49. In terms of profitability, ATOS's ROE is -0.49%, compared to SMMT's ROE of -2.97%. Regarding short-term risk, ATOS is more volatile compared to SMMT. This indicates potentially higher risk in terms of short-term price fluctuations for ATOS.Check SMMT's competition here
ATOS vs JAZZ Comparison March 2026
ATOS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ATOS stands at 39.1M. In comparison, JAZZ has a market cap of 11.2B. Regarding current trading prices, ATOS is priced at $4.53, while JAZZ trades at $182.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ATOS currently has a P/E ratio of -1.31, whereas JAZZ's P/E ratio is -31.22. In terms of profitability, ATOS's ROE is -0.49%, compared to JAZZ's ROE of -0.09%. Regarding short-term risk, ATOS is more volatile compared to JAZZ. This indicates potentially higher risk in terms of short-term price fluctuations for ATOS.Check JAZZ's competition here
ATOS vs EXEL Comparison March 2026
ATOS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ATOS stands at 39.1M. In comparison, EXEL has a market cap of 11.1B. Regarding current trading prices, ATOS is priced at $4.53, while EXEL trades at $41.55.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ATOS currently has a P/E ratio of -1.31, whereas EXEL's P/E ratio is 14.94. In terms of profitability, ATOS's ROE is -0.49%, compared to EXEL's ROE of +0.37%. Regarding short-term risk, ATOS is more volatile compared to EXEL. This indicates potentially higher risk in terms of short-term price fluctuations for ATOS.Check EXEL's competition here
ATOS vs RNAM Comparison March 2026
ATOS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ATOS stands at 39.1M. In comparison, RNAM has a market cap of 10.6B. Regarding current trading prices, ATOS is priced at $4.53, while RNAM trades at $72.86.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ATOS currently has a P/E ratio of -1.31, whereas RNAM's P/E ratio is N/A. In terms of profitability, ATOS's ROE is -0.49%, compared to RNAM's ROE of -0.45%. Regarding short-term risk, ATOS is more volatile compared to RNAM. This indicates potentially higher risk in terms of short-term price fluctuations for ATOS.Check RNAM's competition here
ATOS vs MDGL Comparison March 2026
ATOS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ATOS stands at 39.1M. In comparison, MDGL has a market cap of 9.8B. Regarding current trading prices, ATOS is priced at $4.53, while MDGL trades at $432.83.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ATOS currently has a P/E ratio of -1.31, whereas MDGL's P/E ratio is -33.74. In terms of profitability, ATOS's ROE is -0.49%, compared to MDGL's ROE of -0.44%. Regarding short-term risk, ATOS is more volatile compared to MDGL. This indicates potentially higher risk in terms of short-term price fluctuations for ATOS.Check MDGL's competition here
ATOS vs RXDX Comparison March 2026
ATOS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ATOS stands at 39.1M. In comparison, RXDX has a market cap of 9.6B. Regarding current trading prices, ATOS is priced at $4.53, while RXDX trades at $199.92.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ATOS currently has a P/E ratio of -1.31, whereas RXDX's P/E ratio is -56.47. In terms of profitability, ATOS's ROE is -0.49%, compared to RXDX's ROE of -0.31%. Regarding short-term risk, ATOS is more volatile compared to RXDX. This indicates potentially higher risk in terms of short-term price fluctuations for ATOS.Check RXDX's competition here
ATOS vs IBRX Comparison March 2026
ATOS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ATOS stands at 39.1M. In comparison, IBRX has a market cap of 8.9B. Regarding current trading prices, ATOS is priced at $4.53, while IBRX trades at $8.67.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ATOS currently has a P/E ratio of -1.31, whereas IBRX's P/E ratio is -22.82. In terms of profitability, ATOS's ROE is -0.49%, compared to IBRX's ROE of +0.64%. Regarding short-term risk, ATOS is less volatile compared to IBRX. This indicates potentially lower risk in terms of short-term price fluctuations for ATOS.Check IBRX's competition here
ATOS vs IMGN Comparison March 2026
ATOS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ATOS stands at 39.1M. In comparison, IMGN has a market cap of 8.7B. Regarding current trading prices, ATOS is priced at $4.53, while IMGN trades at $31.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ATOS currently has a P/E ratio of -1.31, whereas IMGN's P/E ratio is -111.55. In terms of profitability, ATOS's ROE is -0.49%, compared to IMGN's ROE of -0.93%. Regarding short-term risk, ATOS is more volatile compared to IMGN. This indicates potentially higher risk in terms of short-term price fluctuations for ATOS.Check IMGN's competition here
ATOS vs PCVX Comparison March 2026
ATOS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ATOS stands at 39.1M. In comparison, PCVX has a market cap of 8.5B. Regarding current trading prices, ATOS is priced at $4.53, while PCVX trades at $59.29.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ATOS currently has a P/E ratio of -1.31, whereas PCVX's P/E ratio is -10.53. In terms of profitability, ATOS's ROE is -0.49%, compared to PCVX's ROE of -0.26%. Regarding short-term risk, ATOS is less volatile compared to PCVX. This indicates potentially lower risk in terms of short-term price fluctuations for ATOS.Check PCVX's competition here
ATOS vs TECH Comparison March 2026
ATOS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ATOS stands at 39.1M. In comparison, TECH has a market cap of 8.4B. Regarding current trading prices, ATOS is priced at $4.53, while TECH trades at $53.89.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ATOS currently has a P/E ratio of -1.31, whereas TECH's P/E ratio is 101.68. In terms of profitability, ATOS's ROE is -0.49%, compared to TECH's ROE of +0.04%. Regarding short-term risk, ATOS is more volatile compared to TECH. This indicates potentially higher risk in terms of short-term price fluctuations for ATOS.Check TECH's competition here
ATOS vs ARWR Comparison March 2026
ATOS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ATOS stands at 39.1M. In comparison, ARWR has a market cap of 8.4B. Regarding current trading prices, ATOS is priced at $4.53, while ARWR trades at $59.82.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ATOS currently has a P/E ratio of -1.31, whereas ARWR's P/E ratio is 37.41. In terms of profitability, ATOS's ROE is -0.49%, compared to ARWR's ROE of +0.36%. Regarding short-term risk, ATOS is less volatile compared to ARWR. This indicates potentially lower risk in terms of short-term price fluctuations for ATOS.Check ARWR's competition here
ATOS vs BPMC Comparison March 2026
ATOS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ATOS stands at 39.1M. In comparison, BPMC has a market cap of 8.4B. Regarding current trading prices, ATOS is priced at $4.53, while BPMC trades at $129.46.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ATOS currently has a P/E ratio of -1.31, whereas BPMC's P/E ratio is -51.58. In terms of profitability, ATOS's ROE is -0.49%, compared to BPMC's ROE of -0.33%. Regarding short-term risk, ATOS is more volatile compared to BPMC. This indicates potentially higher risk in terms of short-term price fluctuations for ATOS.Check BPMC's competition here
ATOS vs AXSM Comparison March 2026
ATOS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ATOS stands at 39.1M. In comparison, AXSM has a market cap of 8.3B. Regarding current trading prices, ATOS is priced at $4.53, while AXSM trades at $162.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ATOS currently has a P/E ratio of -1.31, whereas AXSM's P/E ratio is -44.11. In terms of profitability, ATOS's ROE is -0.49%, compared to AXSM's ROE of -2.54%. Regarding short-term risk, ATOS is more volatile compared to AXSM. This indicates potentially higher risk in terms of short-term price fluctuations for ATOS.Check AXSM's competition here
ATOS vs CERE Comparison March 2026
ATOS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ATOS stands at 39.1M. In comparison, CERE has a market cap of 8.2B. Regarding current trading prices, ATOS is priced at $4.53, while CERE trades at $44.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ATOS currently has a P/E ratio of -1.31, whereas CERE's P/E ratio is -16.47. In terms of profitability, ATOS's ROE is -0.49%, compared to CERE's ROE of -0.72%. Regarding short-term risk, ATOS is more volatile compared to CERE. This indicates potentially higher risk in terms of short-term price fluctuations for ATOS.Check CERE's competition here
ATOS vs HALO Comparison March 2026
ATOS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ATOS stands at 39.1M. In comparison, HALO has a market cap of 8B. Regarding current trading prices, ATOS is priced at $4.53, while HALO trades at $67.37.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ATOS currently has a P/E ratio of -1.31, whereas HALO's P/E ratio is 26.32. In terms of profitability, ATOS's ROE is -0.49%, compared to HALO's ROE of +0.93%. Regarding short-term risk, ATOS is more volatile compared to HALO. This indicates potentially higher risk in terms of short-term price fluctuations for ATOS.Check HALO's competition here
ATOS vs MTSR Comparison March 2026
ATOS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ATOS stands at 39.1M. In comparison, MTSR has a market cap of 7.4B. Regarding current trading prices, ATOS is priced at $4.53, while MTSR trades at $70.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ATOS currently has a P/E ratio of -1.31, whereas MTSR's P/E ratio is -23.58. In terms of profitability, ATOS's ROE is -0.49%, compared to MTSR's ROE of -0.80%. Regarding short-term risk, ATOS is more volatile compared to MTSR. This indicates potentially higher risk in terms of short-term price fluctuations for ATOS.Check MTSR's competition here
ATOS vs KRYS Comparison March 2026
ATOS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ATOS stands at 39.1M. In comparison, KRYS has a market cap of 7.4B. Regarding current trading prices, ATOS is priced at $4.53, while KRYS trades at $253.69.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ATOS currently has a P/E ratio of -1.31, whereas KRYS's P/E ratio is 37.14. In terms of profitability, ATOS's ROE is -0.49%, compared to KRYS's ROE of +0.19%. Regarding short-term risk, ATOS is more volatile compared to KRYS. This indicates potentially higher risk in terms of short-term price fluctuations for ATOS.Check KRYS's competition here
ATOS vs CYTK Comparison March 2026
ATOS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ATOS stands at 39.1M. In comparison, CYTK has a market cap of 7.4B. Regarding current trading prices, ATOS is priced at $4.53, while CYTK trades at $60.41.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ATOS currently has a P/E ratio of -1.31, whereas CYTK's P/E ratio is -9.24. In terms of profitability, ATOS's ROE is -0.49%, compared to CYTK's ROE of +1.73%. Regarding short-term risk, ATOS is more volatile compared to CYTK. This indicates potentially higher risk in terms of short-term price fluctuations for ATOS.Check CYTK's competition here
ATOS vs NUVL Comparison March 2026
ATOS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ATOS stands at 39.1M. In comparison, NUVL has a market cap of 7.2B. Regarding current trading prices, ATOS is priced at $4.53, while NUVL trades at $99.41.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ATOS currently has a P/E ratio of -1.31, whereas NUVL's P/E ratio is -16.99. In terms of profitability, ATOS's ROE is -0.49%, compared to NUVL's ROE of -0.42%. Regarding short-term risk, ATOS is more volatile compared to NUVL. This indicates potentially higher risk in terms of short-term price fluctuations for ATOS.Check NUVL's competition here
ATOS vs ABVX Comparison March 2026
ATOS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ATOS stands at 39.1M. In comparison, ABVX has a market cap of 7.2B. Regarding current trading prices, ATOS is priced at $4.53, while ABVX trades at $109.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ATOS currently has a P/E ratio of -1.31, whereas ABVX's P/E ratio is -21.12. In terms of profitability, ATOS's ROE is -0.49%, compared to ABVX's ROE of +50.78%. Regarding short-term risk, ATOS is more volatile compared to ABVX. This indicates potentially higher risk in terms of short-term price fluctuations for ATOS.Check ABVX's competition here
ATOS vs MRUS Comparison March 2026
ATOS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ATOS stands at 39.1M. In comparison, MRUS has a market cap of 6.8B. Regarding current trading prices, ATOS is priced at $4.53, while MRUS trades at $90.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ATOS currently has a P/E ratio of -1.31, whereas MRUS's P/E ratio is -17.05. In terms of profitability, ATOS's ROE is -0.49%, compared to MRUS's ROE of -0.51%. Regarding short-term risk, ATOS is more volatile compared to MRUS. This indicates potentially higher risk in terms of short-term price fluctuations for ATOS.Check MRUS's competition here
ATOS vs ACLX Comparison March 2026
ATOS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ATOS stands at 39.1M. In comparison, ACLX has a market cap of 6.7B. Regarding current trading prices, ATOS is priced at $4.53, while ACLX trades at $114.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ATOS currently has a P/E ratio of -1.31, whereas ACLX's P/E ratio is -28.09. In terms of profitability, ATOS's ROE is -0.49%, compared to ACLX's ROE of -0.55%. Regarding short-term risk, ATOS is more volatile compared to ACLX. This indicates potentially higher risk in terms of short-term price fluctuations for ATOS.Check ACLX's competition here
ATOS vs KYMR Comparison March 2026
ATOS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ATOS stands at 39.1M. In comparison, KYMR has a market cap of 6.7B. Regarding current trading prices, ATOS is priced at $4.53, while KYMR trades at $83.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ATOS currently has a P/E ratio of -1.31, whereas KYMR's P/E ratio is -23.19. In terms of profitability, ATOS's ROE is -0.49%, compared to KYMR's ROE of -0.29%. Regarding short-term risk, ATOS is more volatile compared to KYMR. This indicates potentially higher risk in terms of short-term price fluctuations for ATOS.Check KYMR's competition here
ATOS vs PRAX Comparison March 2026
ATOS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ATOS stands at 39.1M. In comparison, PRAX has a market cap of 6.6B. Regarding current trading prices, ATOS is priced at $4.53, while PRAX trades at $310.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ATOS currently has a P/E ratio of -1.31, whereas PRAX's P/E ratio is -23.03. In terms of profitability, ATOS's ROE is -0.49%, compared to PRAX's ROE of -0.59%. Regarding short-term risk, ATOS is more volatile compared to PRAX. This indicates potentially higher risk in terms of short-term price fluctuations for ATOS.Check PRAX's competition here
ATOS vs RETA Comparison March 2026
ATOS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ATOS stands at 39.1M. In comparison, RETA has a market cap of 6.6B. Regarding current trading prices, ATOS is priced at $4.53, while RETA trades at $172.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ATOS currently has a P/E ratio of -1.31, whereas RETA's P/E ratio is -66.29. In terms of profitability, ATOS's ROE is -0.49%, compared to RETA's ROE of +0.47%. Regarding short-term risk, ATOS is more volatile compared to RETA. This indicates potentially higher risk in terms of short-term price fluctuations for ATOS.Check RETA's competition here
ATOS vs BLTE Comparison March 2026
ATOS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ATOS stands at 39.1M. In comparison, BLTE has a market cap of 6.5B. Regarding current trading prices, ATOS is priced at $4.53, while BLTE trades at $173.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ATOS currently has a P/E ratio of -1.31, whereas BLTE's P/E ratio is -90.26. In terms of profitability, ATOS's ROE is -0.49%, compared to BLTE's ROE of -0.34%. Regarding short-term risk, ATOS is less volatile compared to BLTE. This indicates potentially lower risk in terms of short-term price fluctuations for ATOS.Check BLTE's competition here
ATOS vs RYTM Comparison March 2026
ATOS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ATOS stands at 39.1M. In comparison, RYTM has a market cap of 6.2B. Regarding current trading prices, ATOS is priced at $4.53, while RYTM trades at $93.52.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ATOS currently has a P/E ratio of -1.31, whereas RYTM's P/E ratio is -30.17. In terms of profitability, ATOS's ROE is -0.49%, compared to RYTM's ROE of -1.79%. Regarding short-term risk, ATOS is less volatile compared to RYTM. This indicates potentially lower risk in terms of short-term price fluctuations for ATOS.Check RYTM's competition here
ATOS vs COGT Comparison March 2026
ATOS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ATOS stands at 39.1M. In comparison, COGT has a market cap of 6B. Regarding current trading prices, ATOS is priced at $4.53, while COGT trades at $37.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ATOS currently has a P/E ratio of -1.31, whereas COGT's P/E ratio is -17.17. In terms of profitability, ATOS's ROE is -0.49%, compared to COGT's ROE of -1.00%. Regarding short-term risk, ATOS is less volatile compared to COGT. This indicates potentially lower risk in terms of short-term price fluctuations for ATOS.Check COGT's competition here
ATOS vs PTGX Comparison March 2026
ATOS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ATOS stands at 39.1M. In comparison, PTGX has a market cap of 5.9B. Regarding current trading prices, ATOS is priced at $4.53, while PTGX trades at $92.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ATOS currently has a P/E ratio of -1.31, whereas PTGX's P/E ratio is -44.92. In terms of profitability, ATOS's ROE is -0.49%, compared to PTGX's ROE of -0.20%. Regarding short-term risk, ATOS is less volatile compared to PTGX. This indicates potentially lower risk in terms of short-term price fluctuations for ATOS.Check PTGX's competition here
ATOS vs CDTX Comparison March 2026
ATOS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ATOS stands at 39.1M. In comparison, CDTX has a market cap of 5.6B. Regarding current trading prices, ATOS is priced at $4.53, while CDTX trades at $221.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ATOS currently has a P/E ratio of -1.31, whereas CDTX's P/E ratio is -19.77. In terms of profitability, ATOS's ROE is -0.49%, compared to CDTX's ROE of -0.60%. Regarding short-term risk, ATOS is more volatile compared to CDTX. This indicates potentially higher risk in terms of short-term price fluctuations for ATOS.Check CDTX's competition here
ATOS vs ABCM Comparison March 2026
ATOS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ATOS stands at 39.1M. In comparison, ABCM has a market cap of 5.5B. Regarding current trading prices, ATOS is priced at $4.53, while ABCM trades at $23.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ATOS currently has a P/E ratio of -1.31, whereas ABCM's P/E ratio is 2399.00. In terms of profitability, ATOS's ROE is -0.49%, compared to ABCM's ROE of -0.01%. Regarding short-term risk, ATOS is more volatile compared to ABCM. This indicates potentially higher risk in terms of short-term price fluctuations for ATOS.Check ABCM's competition here
ATOS vs ISEE Comparison March 2026
ATOS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ATOS stands at 39.1M. In comparison, ISEE has a market cap of 5.5B. Regarding current trading prices, ATOS is priced at $4.53, while ISEE trades at $39.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ATOS currently has a P/E ratio of -1.31, whereas ISEE's P/E ratio is -22.44. In terms of profitability, ATOS's ROE is -0.49%, compared to ISEE's ROE of -0.39%. Regarding short-term risk, ATOS is more volatile compared to ISEE. This indicates potentially higher risk in terms of short-term price fluctuations for ATOS.Check ISEE's competition here
ATOS vs IMVT Comparison March 2026
ATOS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ATOS stands at 39.1M. In comparison, IMVT has a market cap of 5.4B. Regarding current trading prices, ATOS is priced at $4.53, while IMVT trades at $26.66.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ATOS currently has a P/E ratio of -1.31, whereas IMVT's P/E ratio is -9.99. In terms of profitability, ATOS's ROE is -0.49%, compared to IMVT's ROE of -0.66%. Regarding short-term risk, ATOS is more volatile compared to IMVT. This indicates potentially higher risk in terms of short-term price fluctuations for ATOS.Check IMVT's competition here
ATOS vs CRSP Comparison March 2026
ATOS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ATOS stands at 39.1M. In comparison, CRSP has a market cap of 5.4B. Regarding current trading prices, ATOS is priced at $4.53, while CRSP trades at $56.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ATOS currently has a P/E ratio of -1.31, whereas CRSP's P/E ratio is -9.14. In terms of profitability, ATOS's ROE is -0.49%, compared to CRSP's ROE of -0.32%. Regarding short-term risk, ATOS is more volatile compared to CRSP. This indicates potentially higher risk in terms of short-term price fluctuations for ATOS.Check CRSP's competition here
ATOS vs FBIOX Comparison March 2026
ATOS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ATOS stands at 39.1M. In comparison, FBIOX has a market cap of 5.4B. Regarding current trading prices, ATOS is priced at $4.53, while FBIOX trades at $25.21.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ATOS currently has a P/E ratio of -1.31, whereas FBIOX's P/E ratio is N/A. In terms of profitability, ATOS's ROE is -0.49%, compared to FBIOX's ROE of +0.00%. Regarding short-term risk, ATOS is more volatile compared to FBIOX. This indicates potentially higher risk in terms of short-term price fluctuations for ATOS.Check FBIOX's competition here
ATOS vs CELC Comparison March 2026
ATOS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ATOS stands at 39.1M. In comparison, CELC has a market cap of 5.3B. Regarding current trading prices, ATOS is priced at $4.53, while CELC trades at $115.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ATOS currently has a P/E ratio of -1.31, whereas CELC's P/E ratio is -31.25. In terms of profitability, ATOS's ROE is -0.49%, compared to CELC's ROE of -1.79%. Regarding short-term risk, ATOS is less volatile compared to CELC. This indicates potentially lower risk in terms of short-term price fluctuations for ATOS.Check CELC's competition here
ATOS vs CAI Comparison March 2026
ATOS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ATOS stands at 39.1M. In comparison, CAI has a market cap of 5.2B. Regarding current trading prices, ATOS is priced at $4.53, while CAI trades at $18.59.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ATOS currently has a P/E ratio of -1.31, whereas CAI's P/E ratio is -5.28. In terms of profitability, ATOS's ROE is -0.49%, compared to CAI's ROE of +1.97%. Regarding short-term risk, ATOS is more volatile compared to CAI. This indicates potentially higher risk in terms of short-term price fluctuations for ATOS.Check CAI's competition here
ATOS vs PTCT Comparison March 2026
ATOS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ATOS stands at 39.1M. In comparison, PTCT has a market cap of 5.2B. Regarding current trading prices, ATOS is priced at $4.53, while PTCT trades at $62.82.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ATOS currently has a P/E ratio of -1.31, whereas PTCT's P/E ratio is 7.32. In terms of profitability, ATOS's ROE is -0.49%, compared to PTCT's ROE of -3.62%. Regarding short-term risk, ATOS is more volatile compared to PTCT. This indicates potentially higher risk in terms of short-term price fluctuations for ATOS.Check PTCT's competition here
ATOS vs CGON Comparison March 2026
ATOS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ATOS stands at 39.1M. In comparison, CGON has a market cap of 5.1B. Regarding current trading prices, ATOS is priced at $4.53, while CGON trades at $61.88.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ATOS currently has a P/E ratio of -1.31, whereas CGON's P/E ratio is -30.19. In terms of profitability, ATOS's ROE is -0.49%, compared to CGON's ROE of -0.23%. Regarding short-term risk, ATOS is less volatile compared to CGON. This indicates potentially lower risk in terms of short-term price fluctuations for ATOS.Check CGON's competition here
ATOS vs ERAS Comparison March 2026
ATOS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ATOS stands at 39.1M. In comparison, ERAS has a market cap of 4.8B. Regarding current trading prices, ATOS is priced at $4.53, while ERAS trades at $15.47.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ATOS currently has a P/E ratio of -1.31, whereas ERAS's P/E ratio is -35.98. In terms of profitability, ATOS's ROE is -0.49%, compared to ERAS's ROE of -0.33%. Regarding short-term risk, ATOS is less volatile compared to ERAS. This indicates potentially lower risk in terms of short-term price fluctuations for ATOS.Check ERAS's competition here
ATOS vs ALKS Comparison March 2026
ATOS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ATOS stands at 39.1M. In comparison, ALKS has a market cap of 4.8B. Regarding current trading prices, ATOS is priced at $4.53, while ALKS trades at $28.63.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ATOS currently has a P/E ratio of -1.31, whereas ALKS's P/E ratio is 20.02. In terms of profitability, ATOS's ROE is -0.49%, compared to ALKS's ROE of +0.14%. Regarding short-term risk, ATOS is more volatile compared to ALKS. This indicates potentially higher risk in terms of short-term price fluctuations for ATOS.Check ALKS's competition here
ATOS vs TGTX Comparison March 2026
ATOS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ATOS stands at 39.1M. In comparison, TGTX has a market cap of 4.7B. Regarding current trading prices, ATOS is priced at $4.53, while TGTX trades at $29.27.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ATOS currently has a P/E ratio of -1.31, whereas TGTX's P/E ratio is 10.57. In terms of profitability, ATOS's ROE is -0.49%, compared to TGTX's ROE of +1.01%. Regarding short-term risk, ATOS is more volatile compared to TGTX. This indicates potentially higher risk in terms of short-term price fluctuations for ATOS.Check TGTX's competition here
ATOS vs SRRK Comparison March 2026
ATOS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ATOS stands at 39.1M. In comparison, SRRK has a market cap of 4.6B. Regarding current trading prices, ATOS is priced at $4.53, while SRRK trades at $45.29.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ATOS currently has a P/E ratio of -1.31, whereas SRRK's P/E ratio is -14.38. In terms of profitability, ATOS's ROE is -0.49%, compared to SRRK's ROE of -1.46%. Regarding short-term risk, ATOS is more volatile compared to SRRK. This indicates potentially higher risk in terms of short-term price fluctuations for ATOS.Check SRRK's competition here
ATOS vs FOLD Comparison March 2026
ATOS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ATOS stands at 39.1M. In comparison, FOLD has a market cap of 4.5B. Regarding current trading prices, ATOS is priced at $4.53, while FOLD trades at $14.34.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ATOS currently has a P/E ratio of -1.31, whereas FOLD's P/E ratio is -159.22. In terms of profitability, ATOS's ROE is -0.49%, compared to FOLD's ROE of -0.12%. Regarding short-term risk, ATOS is more volatile compared to FOLD. This indicates potentially higher risk in terms of short-term price fluctuations for ATOS.Check FOLD's competition here
ATOS vs AKRO Comparison March 2026
ATOS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ATOS stands at 39.1M. In comparison, AKRO has a market cap of 4.5B. Regarding current trading prices, ATOS is priced at $4.53, while AKRO trades at $54.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ATOS currently has a P/E ratio of -1.31, whereas AKRO's P/E ratio is -14.57. In terms of profitability, ATOS's ROE is -0.49%, compared to AKRO's ROE of -0.31%. Regarding short-term risk, ATOS is more volatile compared to AKRO. This indicates potentially higher risk in terms of short-term price fluctuations for ATOS.Check AKRO's competition here
ATOS vs ALPN Comparison March 2026
ATOS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ATOS stands at 39.1M. In comparison, ALPN has a market cap of 4.5B. Regarding current trading prices, ATOS is priced at $4.53, while ALPN trades at $64.97.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ATOS currently has a P/E ratio of -1.31, whereas ALPN's P/E ratio is -101.52. In terms of profitability, ATOS's ROE is -0.49%, compared to ALPN's ROE of -0.13%. Regarding short-term risk, ATOS is more volatile compared to ALPN. This indicates potentially higher risk in terms of short-term price fluctuations for ATOS.Check ALPN's competition here
ATOS vs MIRM Comparison March 2026
ATOS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ATOS stands at 39.1M. In comparison, MIRM has a market cap of 4.3B. Regarding current trading prices, ATOS is priced at $4.53, while MIRM trades at $86.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ATOS currently has a P/E ratio of -1.31, whereas MIRM's P/E ratio is -183.62. In terms of profitability, ATOS's ROE is -0.49%, compared to MIRM's ROE of -0.09%. Regarding short-term risk, ATOS is more volatile compared to MIRM. This indicates potentially higher risk in terms of short-term price fluctuations for ATOS.Check MIRM's competition here
ATOS vs OPT Comparison March 2026
ATOS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ATOS stands at 39.1M. In comparison, OPT has a market cap of 4.2B. Regarding current trading prices, ATOS is priced at $4.53, while OPT trades at $3.41.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ATOS currently has a P/E ratio of -1.31, whereas OPT's P/E ratio is -1.52. In terms of profitability, ATOS's ROE is -0.49%, compared to OPT's ROE of +0.88%. Regarding short-term risk, ATOS is more volatile compared to OPT. This indicates potentially higher risk in terms of short-term price fluctuations for ATOS.Check OPT's competition here
ATOS vs MRTX Comparison March 2026
ATOS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ATOS stands at 39.1M. In comparison, MRTX has a market cap of 4.1B. Regarding current trading prices, ATOS is priced at $4.53, while MRTX trades at $58.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ATOS currently has a P/E ratio of -1.31, whereas MRTX's P/E ratio is -4.82. In terms of profitability, ATOS's ROE is -0.49%, compared to MRTX's ROE of -0.62%. Regarding short-term risk, ATOS is more volatile compared to MRTX. This indicates potentially higher risk in terms of short-term price fluctuations for ATOS.Check MRTX's competition here
ATOS vs APGE Comparison March 2026
ATOS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ATOS stands at 39.1M. In comparison, APGE has a market cap of 4B. Regarding current trading prices, ATOS is priced at $4.53, while APGE trades at $73.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ATOS currently has a P/E ratio of -1.31, whereas APGE's P/E ratio is -16.68. In terms of profitability, ATOS's ROE is -0.49%, compared to APGE's ROE of -0.37%. Regarding short-term risk, ATOS is less volatile compared to APGE. This indicates potentially lower risk in terms of short-term price fluctuations for ATOS.Check APGE's competition here
ATOS vs LGND Comparison March 2026
ATOS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ATOS stands at 39.1M. In comparison, LGND has a market cap of 4B. Regarding current trading prices, ATOS is priced at $4.53, while LGND trades at $201.90.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ATOS currently has a P/E ratio of -1.31, whereas LGND's P/E ratio is 88.55. In terms of profitability, ATOS's ROE is -0.49%, compared to LGND's ROE of +0.14%. Regarding short-term risk, ATOS is more volatile compared to LGND. This indicates potentially higher risk in terms of short-term price fluctuations for ATOS.Check LGND's competition here
ATOS vs CRNX Comparison March 2026
ATOS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ATOS stands at 39.1M. In comparison, CRNX has a market cap of 3.9B. Regarding current trading prices, ATOS is priced at $4.53, while CRNX trades at $38.23.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ATOS currently has a P/E ratio of -1.31, whereas CRNX's P/E ratio is -8.44. In terms of profitability, ATOS's ROE is -0.49%, compared to CRNX's ROE of -0.41%. Regarding short-term risk, ATOS is less volatile compared to CRNX. This indicates potentially lower risk in terms of short-term price fluctuations for ATOS.Check CRNX's competition here
ATOS vs TERN Comparison March 2026
ATOS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ATOS stands at 39.1M. In comparison, TERN has a market cap of 3.9B. Regarding current trading prices, ATOS is priced at $4.53, while TERN trades at $42.82.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ATOS currently has a P/E ratio of -1.31, whereas TERN's P/E ratio is -41.98. In terms of profitability, ATOS's ROE is -0.49%, compared to TERN's ROE of -0.30%. Regarding short-term risk, ATOS is less volatile compared to TERN. This indicates potentially lower risk in terms of short-term price fluctuations for ATOS.Check TERN's competition here
ATOS vs VKTX Comparison March 2026
ATOS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ATOS stands at 39.1M. In comparison, VKTX has a market cap of 3.8B. Regarding current trading prices, ATOS is priced at $4.53, while VKTX trades at $32.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ATOS currently has a P/E ratio of -1.31, whereas VKTX's P/E ratio is -10.34. In terms of profitability, ATOS's ROE is -0.49%, compared to VKTX's ROE of -0.48%. Regarding short-term risk, ATOS is less volatile compared to VKTX. This indicates potentially lower risk in terms of short-term price fluctuations for ATOS.Check VKTX's competition here
ATOS vs ACAD Comparison March 2026
ATOS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ATOS stands at 39.1M. In comparison, ACAD has a market cap of 3.8B. Regarding current trading prices, ATOS is priced at $4.53, while ACAD trades at $22.16.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ATOS currently has a P/E ratio of -1.31, whereas ACAD's P/E ratio is 9.64. In terms of profitability, ATOS's ROE is -0.49%, compared to ACAD's ROE of +0.42%. Regarding short-term risk, ATOS is more volatile compared to ACAD. This indicates potentially higher risk in terms of short-term price fluctuations for ATOS.Check ACAD's competition here
ATOS vs RYZB Comparison March 2026
ATOS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ATOS stands at 39.1M. In comparison, RYZB has a market cap of 3.8B. Regarding current trading prices, ATOS is priced at $4.53, while RYZB trades at $62.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ATOS currently has a P/E ratio of -1.31, whereas RYZB's P/E ratio is -57.86. In terms of profitability, ATOS's ROE is -0.49%, compared to RYZB's ROE of +0.83%. Regarding short-term risk, ATOS is more volatile compared to RYZB. This indicates potentially higher risk in terms of short-term price fluctuations for ATOS.Check RYZB's competition here
ATOS vs CBAY Comparison March 2026
ATOS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ATOS stands at 39.1M. In comparison, CBAY has a market cap of 3.7B. Regarding current trading prices, ATOS is priced at $4.53, while CBAY trades at $32.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ATOS currently has a P/E ratio of -1.31, whereas CBAY's P/E ratio is -32.81. In terms of profitability, ATOS's ROE is -0.49%, compared to CBAY's ROE of -0.64%. Regarding short-term risk, ATOS is more volatile compared to CBAY. This indicates potentially higher risk in terms of short-term price fluctuations for ATOS.Check CBAY's competition here
ATOS vs ADMA Comparison March 2026
ATOS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ATOS stands at 39.1M. In comparison, ADMA has a market cap of 3.7B. Regarding current trading prices, ATOS is priced at $4.53, while ADMA trades at $15.39.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ATOS currently has a P/E ratio of -1.31, whereas ADMA's P/E ratio is 25.65. In terms of profitability, ATOS's ROE is -0.49%, compared to ADMA's ROE of +0.35%. Regarding short-term risk, ATOS is more volatile compared to ADMA. This indicates potentially higher risk in terms of short-term price fluctuations for ATOS.Check ADMA's competition here
ATOS vs CORT Comparison March 2026
ATOS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ATOS stands at 39.1M. In comparison, CORT has a market cap of 3.6B. Regarding current trading prices, ATOS is priced at $4.53, while CORT trades at $33.87.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ATOS currently has a P/E ratio of -1.31, whereas CORT's P/E ratio is 43.42. In terms of profitability, ATOS's ROE is -0.49%, compared to CORT's ROE of +0.15%. Regarding short-term risk, ATOS is more volatile compared to CORT. This indicates potentially higher risk in terms of short-term price fluctuations for ATOS.Check CORT's competition here
ATOS vs SWTX Comparison March 2026
ATOS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ATOS stands at 39.1M. In comparison, SWTX has a market cap of 3.5B. Regarding current trading prices, ATOS is priced at $4.53, while SWTX trades at $46.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ATOS currently has a P/E ratio of -1.31, whereas SWTX's P/E ratio is -13.78. In terms of profitability, ATOS's ROE is -0.49%, compared to SWTX's ROE of -0.45%. Regarding short-term risk, ATOS is more volatile compared to SWTX. This indicates potentially higher risk in terms of short-term price fluctuations for ATOS.Check SWTX's competition here
ATOS vs CNTA Comparison March 2026
ATOS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ATOS stands at 39.1M. In comparison, CNTA has a market cap of 3.5B. Regarding current trading prices, ATOS is priced at $4.53, while CNTA trades at $25.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ATOS currently has a P/E ratio of -1.31, whereas CNTA's P/E ratio is -13.73. In terms of profitability, ATOS's ROE is -0.49%, compared to CNTA's ROE of -0.68%. Regarding short-term risk, ATOS is more volatile compared to CNTA. This indicates potentially higher risk in terms of short-term price fluctuations for ATOS.Check CNTA's competition here
ATOS vs NAMS Comparison March 2026
ATOS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ATOS stands at 39.1M. In comparison, NAMS has a market cap of 3.4B. Regarding current trading prices, ATOS is priced at $4.53, while NAMS trades at $29.86.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ATOS currently has a P/E ratio of -1.31, whereas NAMS's P/E ratio is -17.36. In terms of profitability, ATOS's ROE is -0.49%, compared to NAMS's ROE of -0.27%. Regarding short-term risk, ATOS is more volatile compared to NAMS. This indicates potentially higher risk in terms of short-term price fluctuations for ATOS.Check NAMS's competition here
ATOS vs KNSA Comparison March 2026
ATOS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ATOS stands at 39.1M. In comparison, KNSA has a market cap of 3.4B. Regarding current trading prices, ATOS is priced at $4.53, while KNSA trades at $46.16.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ATOS currently has a P/E ratio of -1.31, whereas KNSA's P/E ratio is 61.55. In terms of profitability, ATOS's ROE is -0.49%, compared to KNSA's ROE of +0.11%. Regarding short-term risk, ATOS is less volatile compared to KNSA. This indicates potentially lower risk in terms of short-term price fluctuations for ATOS.Check KNSA's competition here
ATOS vs GPCR Comparison March 2026
ATOS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ATOS stands at 39.1M. In comparison, GPCR has a market cap of 3.3B. Regarding current trading prices, ATOS is priced at $4.53, while GPCR trades at $57.73.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ATOS currently has a P/E ratio of -1.31, whereas GPCR's P/E ratio is -15.77. In terms of profitability, ATOS's ROE is -0.49%, compared to GPCR's ROE of -0.15%. Regarding short-term risk, ATOS is more volatile compared to GPCR. This indicates potentially higher risk in terms of short-term price fluctuations for ATOS.Check GPCR's competition here
ATOS vs XENE Comparison March 2026
ATOS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ATOS stands at 39.1M. In comparison, XENE has a market cap of 3.2B. Regarding current trading prices, ATOS is priced at $4.53, while XENE trades at $41.94.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ATOS currently has a P/E ratio of -1.31, whereas XENE's P/E ratio is -10.78. In terms of profitability, ATOS's ROE is -0.49%, compared to XENE's ROE of -0.56%. Regarding short-term risk, ATOS is more volatile compared to XENE. This indicates potentially higher risk in terms of short-term price fluctuations for ATOS.Check XENE's competition here
ATOS vs LQDA Comparison March 2026
ATOS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ATOS stands at 39.1M. In comparison, LQDA has a market cap of 3.1B. Regarding current trading prices, ATOS is priced at $4.53, while LQDA trades at $36.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ATOS currently has a P/E ratio of -1.31, whereas LQDA's P/E ratio is -24.68. In terms of profitability, ATOS's ROE is -0.49%, compared to LQDA's ROE of -2.09%. Regarding short-term risk, ATOS is less volatile compared to LQDA. This indicates potentially lower risk in terms of short-term price fluctuations for ATOS.Check LQDA's competition here
ATOS vs TARS Comparison March 2026
ATOS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ATOS stands at 39.1M. In comparison, TARS has a market cap of 3.1B. Regarding current trading prices, ATOS is priced at $4.53, while TARS trades at $73.26.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ATOS currently has a P/E ratio of -1.31, whereas TARS's P/E ratio is -46.08. In terms of profitability, ATOS's ROE is -0.49%, compared to TARS's ROE of -0.20%. Regarding short-term risk, ATOS is more volatile compared to TARS. This indicates potentially higher risk in terms of short-term price fluctuations for ATOS.Check TARS's competition here
ATOS vs DNLI Comparison March 2026
ATOS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ATOS stands at 39.1M. In comparison, DNLI has a market cap of 3.1B. Regarding current trading prices, ATOS is priced at $4.53, while DNLI trades at $19.69.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ATOS currently has a P/E ratio of -1.31, whereas DNLI's P/E ratio is -6.74. In terms of profitability, ATOS's ROE is -0.49%, compared to DNLI's ROE of -0.50%. Regarding short-term risk, ATOS is more volatile compared to DNLI. This indicates potentially higher risk in terms of short-term price fluctuations for ATOS.Check DNLI's competition here
ATOS vs CPRX Comparison March 2026
ATOS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ATOS stands at 39.1M. In comparison, CPRX has a market cap of 3B. Regarding current trading prices, ATOS is priced at $4.53, while CPRX trades at $24.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ATOS currently has a P/E ratio of -1.31, whereas CPRX's P/E ratio is 14.43. In terms of profitability, ATOS's ROE is -0.49%, compared to CPRX's ROE of +0.24%. Regarding short-term risk, ATOS is more volatile compared to CPRX. This indicates potentially higher risk in terms of short-term price fluctuations for ATOS.Check CPRX's competition here
ATOS vs ARQT Comparison March 2026
ATOS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ATOS stands at 39.1M. In comparison, ARQT has a market cap of 3B. Regarding current trading prices, ATOS is priced at $4.53, while ARQT trades at $24.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ATOS currently has a P/E ratio of -1.31, whereas ARQT's P/E ratio is -70.59. In terms of profitability, ATOS's ROE is -0.49%, compared to ARQT's ROE of -0.10%. Regarding short-term risk, ATOS is more volatile compared to ARQT. This indicates potentially higher risk in terms of short-term price fluctuations for ATOS.Check ARQT's competition here
ATOS vs EWTX Comparison March 2026
ATOS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ATOS stands at 39.1M. In comparison, EWTX has a market cap of 2.9B. Regarding current trading prices, ATOS is priced at $4.53, while EWTX trades at $27.82.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ATOS currently has a P/E ratio of -1.31, whereas EWTX's P/E ratio is -17.72. In terms of profitability, ATOS's ROE is -0.49%, compared to EWTX's ROE of -0.32%. Regarding short-term risk, ATOS is more volatile compared to EWTX. This indicates potentially higher risk in terms of short-term price fluctuations for ATOS.Check EWTX's competition here
ATOS vs IDYA Comparison March 2026
ATOS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ATOS stands at 39.1M. In comparison, IDYA has a market cap of 2.9B. Regarding current trading prices, ATOS is priced at $4.53, while IDYA trades at $33.19.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ATOS currently has a P/E ratio of -1.31, whereas IDYA's P/E ratio is -25.93. In terms of profitability, ATOS's ROE is -0.49%, compared to IDYA's ROE of -0.11%. Regarding short-term risk, ATOS is more volatile compared to IDYA. This indicates potentially higher risk in terms of short-term price fluctuations for ATOS.Check IDYA's competition here
ATOS vs MORF Comparison March 2026
ATOS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ATOS stands at 39.1M. In comparison, MORF has a market cap of 2.9B. Regarding current trading prices, ATOS is priced at $4.53, while MORF trades at $56.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ATOS currently has a P/E ratio of -1.31, whereas MORF's P/E ratio is -14.88. In terms of profitability, ATOS's ROE is -0.49%, compared to MORF's ROE of -0.29%. Regarding short-term risk, ATOS is more volatile compared to MORF. This indicates potentially higher risk in terms of short-term price fluctuations for ATOS.Check MORF's competition here
ATOS vs MOR Comparison March 2026
ATOS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ATOS stands at 39.1M. In comparison, MOR has a market cap of 2.9B. Regarding current trading prices, ATOS is priced at $4.53, while MOR trades at $18.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ATOS currently has a P/E ratio of -1.31, whereas MOR's P/E ratio is -12.64. In terms of profitability, ATOS's ROE is -0.49%, compared to MOR's ROE of -1.84%. Regarding short-term risk, ATOS is more volatile compared to MOR. This indicates potentially higher risk in terms of short-term price fluctuations for ATOS.Check MOR's competition here
ATOS vs ALMS Comparison March 2026
ATOS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ATOS stands at 39.1M. In comparison, ALMS has a market cap of 2.8B. Regarding current trading prices, ATOS is priced at $4.53, while ALMS trades at $26.90.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ATOS currently has a P/E ratio of -1.31, whereas ALMS's P/E ratio is -12.51. In terms of profitability, ATOS's ROE is -0.49%, compared to ALMS's ROE of -0.76%. Regarding short-term risk, ATOS is less volatile compared to ALMS. This indicates potentially lower risk in terms of short-term price fluctuations for ATOS.Check ALMS's competition here
ATOS vs VERA Comparison March 2026
ATOS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ATOS stands at 39.1M. In comparison, VERA has a market cap of 2.8B. Regarding current trading prices, ATOS is priced at $4.53, while VERA trades at $39.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ATOS currently has a P/E ratio of -1.31, whereas VERA's P/E ratio is -8.38. In terms of profitability, ATOS's ROE is -0.49%, compared to VERA's ROE of -0.60%. Regarding short-term risk, ATOS is more volatile compared to VERA. This indicates potentially higher risk in terms of short-term price fluctuations for ATOS.Check VERA's competition here
ATOS vs KDNY Comparison March 2026
ATOS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ATOS stands at 39.1M. In comparison, KDNY has a market cap of 2.7B. Regarding current trading prices, ATOS is priced at $4.53, while KDNY trades at $40.39.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ATOS currently has a P/E ratio of -1.31, whereas KDNY's P/E ratio is -12.47. In terms of profitability, ATOS's ROE is -0.49%, compared to KDNY's ROE of -0.41%. Regarding short-term risk, ATOS is more volatile compared to KDNY. This indicates potentially higher risk in terms of short-term price fluctuations for ATOS.Check KDNY's competition here